Evan Z. Kovac

Dr. Evan Z. Kovac

Urology, Rutgers Cancer Institute of New Jersey, Newark, New Jersey, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
KWKara L Watts
Kara L Watts
LFLaena Frechette
Laena Frechette
BMBen Muller
Ben Muller
DIDan Ilinksy
Dan Ilinksy
Evan Z. KovacEvan Z. Kovac
Evan Z. Kovac
AAAhmed Aboumohamed
Ahmed Aboumohamed

22 June 2018 in BJU International
Verified
Journal Article
Closed access
PDF file
Evan Z. KovacEvan Z. Kovac
Evan Z. Kovac
EVEmily A. Vertosick
Emily A. Vertosick
DSDaniel D. Sjoberg
Daniel D. Sjoberg
AVAndrew J. Vickers
Andrew J. Vickers
ASAndrew J. Stephenson
Andrew J. Stephenson

3 January 2020 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
Evan Z. KovacEvan Z. Kovac
Evan Z. Kovac
SCSigrid V. Carlsson
Sigrid V. Carlsson
HLHans Lilja
Hans Lilja
JHJonas Hugosson
Jonas Hugosson
MKMichael W. Kattan
Michael W. Kattan
ASAndrew J. Stephenson
Andrew J. Stephenson
Since the introduction of widespread prostate-specific antigen (PSA) screening in the early 1990s, diagnosis and radical treatment of prostate cancer (PCa) has led to a 50% reduction in PCa-specific mortality since peak rates.1 While PSA screening was once widely accepted and ubiquitous, opinions on the utility of screening have shifted in recent years, and there is now controversy surrounding its use as a screening tool because of the overdiagnosis and overtreatment of indolent cancers.2 The concern over the utility of PSA as a screening tool was highlighted by the United States Preventive Services Task Force recommendation against PSA screening in 2012,3 although recently the task force has revised its statement to promote shared decision-making between patients and physicians.4 This position has factored in the increased use of active surveillance for men with low-risk PCa, as defined by the American Urological Association.5,6

10 December 2021 in Cancer
Verified
Journal Article
Closed access
PDF file
JTJon C. Tilburt
Jon C. Tilburt
David ZahriehDavid Zahrieh
David Zahrieh
JPJoel Pacyna
Joel Pacyna
DPDaniel G. Petereit
Daniel G. Petereit
JKJudith S. Kaur
Judith S. Kaur
SKSimon P. Kim
Simon P. Kim

1 July 2021 in Journal of Urology
Verified
Journal Article
Closed access
DZDenzel Zhu
Denzel Zhu
ASAbhishek Srivastava
Abhishek Srivastava
IAIlir Agalliu
Ilir Agalliu
EFEthan Fram
Ethan Fram
Evan Z. KovacEvan Z. Kovac
Evan Z. Kovac
ASAlexander I. Sankin
Alexander I. Sankin
Purpose: Finasteride use has been associated with a reduced incidence of bladder cancer (BCa). However, the majority of studies have been conducted primarily in East Asian or Caucasian populations. Given differences in the incidence of BCa among racial/ethnic groups, it is important to determine whether the effect of finasteride use on BCa varies by race/ethnicity. Materials and Methods: We identified all patients with a diagnosis of benign prostatic hypertrophy (BPH) between 2000 and 2016 at our academic health center in Bronx, NY, via an electronic medical record database. We then identified patients who were prescribed finasteride, and those that developed BCa during follow-up. We used competing risk analysis to examine associations of finasteride use with risk of BCa, adjusting for age, smoking and race/ethnicity. Results: We identified 42,406 patients with BPH (average age 67±12.9 years), of whom 27.7% were African American and 14.8% were Hispanic. Finasteride was prescribed in 5,698 (13.4%) patients. BCa was diagnosed in 84 of 5,698 (1.5%) finasteride-users, compared to 762 of 36,708 (2.1%) non-users (log-rank p=0.003). Finasteride was associated with a 36% reduction in risk of BCa (HR: 0.64, 95% CI: 0.51-0.80, p <0.0001) among all patients. When data were stratified by race/ethnicity, finasteride use was associated with a reduction in risk of BCa in Caucasians (HR: 0.61, 95% CI: 0.43-0.86, p=0.005) and Hispanic men (HR: 0.44, 95% CI: 0.21-0.90, p=0.026), but there was no association among African American men (HR: 1.01, 95%CI: 0.67–1.51, p=0.964). Conclusions: Our study corroborates previous findings that men who are on finasteride have a lower BCa incidence. However, the reduction in risk was seen only in Caucasians and Hispanics, but not among African Americans. Therefore, race/ethnicity represents an important stratification factor for future larger studies on finasteride as chemoprevention for BCa.

14 July 2015 in The Prostate
Verified
Journal Article
Closed access
PDF file
AEAhmed Elshafei
Ahmed Elshafei
Evan Z. KovacEvan Z. Kovac
Evan Z. Kovac
NDNivedita Dhar
Nivedita Dhar
DLDavid Levy
David Levy
TPThomas Polascik
Thomas Polascik
JJJ. Stephen Jones
J. Stephen Jones